Brief: United Laboratories International Says Group's Product Cefotaxime Sodium For Injection Passed Consistency Evaluation
15/04/2025 11:30
April 15 (Reuters) - United Laboratories International Holdings Ltd 3933.HK: GROUP'S PRODUCT CEFOTAXIME SODIUM FOR INJECTION PASSED CONSISTENCY EVALUATION FROM NMPA Further company coverage: 3933.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million